8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
About 70% of S&P 500 Names Beat EPS, While 47% Soar Past Revenue Estimates This Week - Earnings Scorecard
Viatris Inc. (VTRS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Strategic Shifts and ...
UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating
Viatris (VTRS) has an average rating of Hold and price targets ranging from $11 to $14, according to analysts polled by Capital IQ. Price: 11.19, Change: -0.03, Percent Change: -0.27
Viatris To Go Ex-Dividend On May 23rd, 2024 With 0.12 USD Dividend Per Share
May 10th - $Viatris(VTRS.US)$ is trading ex-dividend on May 23rd, 2024. Shareholders of record on May 24th, 2024 will receive 0.12 USD dividend per share on June 14th, 2024. The ex-dividend date i
Viatris | 10-Q: Quarterly report
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $13
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Thursday, Viatris Inc (NASDAQ:VTRS) reported first-quarter EPS of $0.67, which is in line with the consensus.The company reported sales of $3.66 billion, missing the consensus of $3.69 billion. Total
Earnings Call Summary | Viatris(VTRS.US) Q1 2024 Earnings Conference
The following is a summary of the Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript:Financial Performance:Viatris reported Q1 revenue of approximately $3.7 billion, adjusted EBITDA of approximately
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve i
Viatris Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Viatris Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Viatris Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $1 to $1
Viagra Maker Viatris Misses Revenue Estimates on Weak Demand for Older Drugs
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced
Viatris (VTRS) reported Q1 adjusted earnings Thursday of $0.67 per diluted share, down from $0.77 a year earlier. Analysts polled by Capital IQ expected $0.67. Total revenue for the quarter ended Marc
GUIDANCE: (VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B
07:02 AM EDT, 05/09/2024 (MT Newswires) -- GUIDANCE: (VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B
Viatris Cuts FY24 View To Adj EPS $2.66-Adj EPS $2.81 >VTRS
Viatris Cuts FY24 View To Adj EPS $2.66-Adj EPS $2.81 >VTRS
Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, Vs. Street Est of $0.67
06:59 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, vs. Street Est of $0.67
Viatris 1Q Rev $3.66B >VTRS
Viatris 1Q Rev $3.66B >VTRS
Press Release: Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges PR Newswire PITTSBURGH, May 9, 2024 PITTSBURGH, May 9, 2024 /PRNewswire/ -- -- Reports T
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
No Data